Evidence map›Paper›PMID 30401621›Full record

ArticleVaccine2018

Investigation of group A Streptococcus immune responses in an endemic setting, with a particular focus on J8.

Patricia Therese Campbell, Hannah Frost, Pierre R Smeesters, Joseph Kado, Michael F Good, Michael Batzloff, Nicholas Geard, Jodie McVernon, Andrew Steer

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 3 countries.

Patricia Therese CampbellVictorian Infectious Diseases Reference Laboratory Epidemiology Unit, The Peter Doherty Institute for Infection and Immunity, The Royal Melbourne Hospital and The University of Melbourne, Australia; Murdoch Children's Research Institute, The Royal Children's Hospital, Melbourne, Australia. Electronic address: patricia.campbell@unimelb.edu.au.
Hannah FrostMurdoch Children's Research Institute, The Royal Children's Hospital, Melbourne, Australia; Molecular Bacteriology Laboratory, Université Libre de Bruxelles, Brussels, Belgium.
Pierre R SmeestersMurdoch Children's Research Institute, The Royal Children's Hospital, Melbourne, Australia; Molecular Bacteriology Laboratory, Université Libre de Bruxelles, Brussels, Belgium; Department of Pediatrics, Academic Children Hospital Queen Fabiola, Université Libre de Bruxelles, Brussels, Belgium; Centre for International Child Health, University of Melbourne, Australia.
Joseph KadoDepartment of Paediatrics, Colonial War Memorial Hospital, Fiji; College of Medicine, Nursing and Health Sciences, Fiji National University, Fiji; Fiji Rheumatic Heart Disease Control Program, Suva, Fiji; Telethon Kids Institute, University of Western Australia, Perth, Western, Australia.
Michael F GoodInstitute for Glycomics, Griffith University, Gold Coast, Queensland, Australia.
Michael BatzloffQueensland Institute of Medical Research, Brisbane, Queensland, Australia.
Nicholas GeardVictorian Infectious Diseases Reference Laboratory Epidemiology Unit, The Peter Doherty Institute for Infection and Immunity, The Royal Melbourne Hospital and The University of Melbourne, Australia; School of Computing and Information Systems, Melbourne School of Engineering, The University of Melbourne, Australia.
Jodie McVernonVictorian Infectious Diseases Reference Laboratory Epidemiology Unit, The Peter Doherty Institute for Infection and Immunity, The Royal Melbourne Hospital and The University of Melbourne, Australia; Murdoch Children's Research Institute, The Royal Children's Hospital, Melbourne, Australia; Melbourne School of Population and Global Health, The University of Melbourne, Australia.
Andrew SteerMurdoch Children's Research Institute, The Royal Children's Hospital, Melbourne, Australia; Centre for International Child Health, University of Melbourne, Australia; Department of Paediatrics, University of Melbourne, Royal Children's Hospital Melbourne, Parkville, Australia.
Murdoch Children's Research Institute · AUFiji National University · FJGriffith University · AUPeter Doherty Institute · AUQIMR Berghofer Medical Research Institute · AURoyal Children's Hospital · AUVictorian Infectious Diseases Reference Laboratory · AU

Funding

Global GAS Vaccine Based On The M-ProteinU01AI060579 · NIAID · QUEENSLAND INSTITUTE OF MEDICAL RESEARCH · PI GOOD, MICHAEL F · 2004 to 2008
$2.8M
NIAID NIH HHS U01 AI060579
6 · The paper itself

Abstract

Sustained control of group A Streptococcus (GAS) infections in settings of poverty has proven to be challenging, and an effective vaccine may be the most practical long-term strategy to reduce GAS-related disease burden. Candidate GAS vaccines based on the J8 peptide have demonstrated promising immunogenicity in mice, however, less is known about the role of J8 antibodies in the human immune response to GAS infection. We analysed the stimulation of J8 antibodies in response to infection, and the role of existing J8 antibodies in protection against subsequent infection, using data collected in the Fijian population: (1) cross sectional population serosurvey; (2) paired serum collection for assessment of M-specific and J8 antibody responses; and (3) longitudinal assessment of GAS infection and immunity. Median J8 antibody concentrations peaked in the 5-14 year age group, but there was no sustained increase with age. J8 antibody concentration was neither a significant predictor of time to next infection, nor did it show any relationship to the time since last recorded skin infection. Similarly, J8 antibody fold changes over a defined period were associated neither with the time since last skin infection, nor the number of intervening skin infections. While strong M-specific antibody responses were observed for skin infection, similarly strong J8 antibody responses were not observed. There is no indication that antibodies to the J8 antigen would be useful as either a marker of GAS infection or a measure of population immunity, with J8 antibody responses to infection fleeting, if existent at all.

Indexed as

Endemic DiseasesAdolescentAdultAgedAge FactorsAnimalsAntibodies, BacterialAntigens, BacterialChildChild, PreschoolCross-Sectional StudiesFijiHumansInfantInfant, NewbornLongitudinal StudiesAntibodies, BacterialAntigens, BacterialGroup A StreptococcusImmunityImpetigoJ8Vaccine antigen

Identifiers

PMID30401621
PMCPMC6296486
OpenAlexW2899331834

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.